

Important Medical Information

A New Era In Cervical Cancer Prevention

Mater Pathology performs on site **High-Risk HPV DNA testing** using the **Digene HPV Hybrid Capture II Test**. Mater Pathology was the first laboratory in Queensland to perform this test on site, reflecting its passionate interest in Women's Health Diagnostics. The **Digene HPV Hybrid Capture II Test** complements the laboratory's Pap smear and Thin Prep Cytology Service.

The **Digene HPV Hybrid Capture II Test** is used to identify the presence of high-risk HPV types in samples taken from the lower female genital tract. The test is run on the latest Digene Hybrid-Capture® technology platform, and detects the high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 & 68.

The results help to optimise the management of cervical cancer risk by

- Confirmation of HPV eradication after previous cone or LLETZ biopsy.
- Resolving equivocal and discrepant colposcopic, histologic and cytologic findings.

The Digene HPV Hybrid Capture II Test is the most advanced tool for detection of high-risk HPV DNA in cervical samples and is used beneficially in combination with standard and ThinPrep cervical cytology.

The Digene HPV Hybrid Capture II Test has:

- Sensitivity for high-grade squamous lesions (CIN 2/3+) of >96%
- A negative predictive value of >99.2%
- Validation for use for HPV detection confirmed in over 300 publications
- Has demonstrated better clinical accuracy than PCR-based HPV detection
- Detects the 13 most clinically relevant high-risk HPV types

The **Digene HPV Hybrid Capture II Test** is the only HPV test approved by the FDA and has been recommended by the American College of Obstetricians and Gynecologists for use in routine cervical screening in women >30 years.

The test is Medicare Rebatable in patients previously treated for high-grade cervical lesions (turn page over for more details).

Item Number: 69486 (Medicare rebate)

A test for high risk human papilloma viruses (HPV) in a patient who:

- has received excisional or ablative treatment for high grade squamous intraepithelial lesions (HSIL) of the cervix within the last two years; or
- who within the last two years has had a positive HPV test after excisional or ablative treatment for HSIL of the cervix
- is already undergoing annual cytological review for the follow-up of a previously treated HSIL
- to a maximum of 2 of this item in a 24 month period

Cost when not Medicare rebatable : The total fee to the patient is **\$78.00** (Incl. GST).

The **Digene HPV Hybrid Capture II Test** can be readily performed on the same patient samples collected for ThinPrep (liquid based) cytology. Alternatively a cervical sample can be collected using the Digene Cervical Sampler.

For further information in relation to the HPV DNA test, please contact our specialist gynaecological Pathologists:

Associate Prof. Jane Armes

(Director, Anatomic Pathology)

Phone: 3163 8500

Mobile: 0418 328 917

Dr. Rohan Lourie

(Consultant Pathologist)

Phone: 3163 8500.

Mater Pathology is a not-for-profit organisation. Revenues raised are reinvested into Community Health Services and Research.

www.mater.org.au/pathology